Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

Hologic (HOLX.O) rejected a non-binding take-private proposal from TPG (TPG.O) and Blackstone (BX.N) valuing the company at $70-$72 per share, a 30% premium to Friday's close, according to the Financial Times. The offer, totaling up to $16.7 billion, could become one of the year's largest leveraged buyouts, though talks could be revived. Hologic previously lowered its fiscal 2025 profit forecast, citing tariff uncertainty and lower demand for gantry placements.

Analysis

Medical equipment manufacturer Hologic (HOLX.O) rejected a non-binding take-private proposal from private equity firms TPG (TPG.O) and Blackstone (BX.N), valued at $70-$72 per share, totaling up to $16.7 billion. This offer represented an approximate 30% premium to Hologic's closing price of $54.28 on the Friday prior to the report, and news of the rejected bid spurred a 15.1% increase in Hologic's shares during afternoon trading. The rejection comes despite Hologic having recently lowered its fiscal 2025 profit forecast, citing uncertainty surrounding U.S. tariffs and an anticipated decrease in demand for gantry placements. Although declined, the possibility remains that deal talks could be revived, positioning this potential transaction as one of the largest leveraged buyouts of the year. The situation underscores a divergence in valuation perspectives, with private equity identifying significant potential despite publicly communicated operational challenges and a cautious near-term outlook from the company.

Key Decisions for Investors

• Investors in Hologic should re-evaluate their positions, considering the board's implicit view that the company's standalone value or potential for a higher bid exceeds the $70-$72 per share offer, balanced against the recently lowered fiscal 2025 profit forecast and associated risks.
• Market participants should monitor Hologic for any signs of revived negotiations or interest from other parties, as the current share price may not fully capture a potential final acquisition price if a deal materializes, though downside exists if no further offers emerge.
• The substantial premium offered by TPG and Blackstone, despite Hologic's cautious guidance, suggests strong private equity interest in the medical equipment sector; this may indicate perceived undervaluation or strategic opportunities in comparable companies within the industry.